AI Trials in Cardiovascular Care Have Grown Quickly, but the Evidence Remains Uneven
Artificial intelligence has moved from speculative promise to active testing in cardiology, and the scale of the randomized evidence is now large enough to judge its contours. A systematic review and meta-analysis of AI-enabled cardiovascular care identified 31 randomized controlled trials from 13 regions, enrolling 1,685,717 patients in the full review and 1,614,689 in the meta-analysis. Even with that patient volume, the trial base is still marked by fragmentation: most studies were published after 2021, most were multicenter, and most had short follow-up. The picture is substantial in size but uneven in maturity.
A Broad Search Captured 31 Randomized Trials Across 13 Regions
The review searched Embase, MEDLINE, Scopus, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for randomized trials of AI interventions in cardiovascular care published in English from database inception through July 7, 2025, with an update on April 28, 2026. The investigators followed Cochrane guidance for study selection and data extraction, then assessed risk of bias with Cochrane tools and reporting transparency with the CONSORT-AI checklist. Summary effects were calculated with inverse-variance-weighted random-effects meta-analyses, and certainty of evidence was graded with GRADE. Publication bias was not assessed because the number of studies was too small for that analysis.
Those methods matter because AI trials often differ in the details that determine whether a tool can be used at the bedside. The intervention may be embedded in screening, diagnosis, triage, prognostication, or treatment support, yet the underlying algorithm, input data, workflow position, and comparator can all vary. A review that only counts studies without examining design would miss the practical barriers that decide whether an algorithm improves care or simply adds complexity.
Most Studies Were Recent, Multicenter, and Short-Term
The trial profile suggests a field in rapid expansion rather than one with settled standards. Nearly all included RCTs were published after 2021, and 58% were multicenter. Short follow-up was common. Those features signal a research area that is still testing feasibility, implementation, and early clinical signal rather than long-horizon cardiovascular outcomes.
One sentence captures the central tension in the evidence base: the volume is large, but the trial structure remains young.
Cardiovascular care is particularly sensitive to this problem. A triage tool that speeds referral, a model that improves image interpretation, or a risk algorithm that changes medication decisions may show immediate operational benefit without yet proving durable effects on myocardial infarction, stroke, heart failure hospitalization, or mortality. Short follow-up can detect early workflow changes, but it does not answer the harder question of whether AI meaningfully alters the disease course.
Methodological Quality and Reporting Transparency Became Part of the Question
This review did not stop at outcome pooling. It explicitly evaluated methodological quality and reporting transparency, acknowledging that AI studies can fail in ways that are not visible from headline results alone. Randomized trials may be vulnerable to unclear allocation procedures, incomplete masking, selective reporting, and inconsistent description of the intervention itself. In AI research, those risks can be amplified when investigators do not fully describe the training data, model architecture, validation approach, or deployment setting.
The use of the CONSORT-AI checklist is especially relevant because reporting quality determines whether readers can understand what was actually tested. An AI system that performs well in one hospital may not behave the same way elsewhere if patient mix, imaging protocols, workflow integration, or local thresholds differ. Transparent reporting is not a cosmetic issue; it is the only way to judge whether a result can be reproduced outside the trial site.
The Meta-Analysis Is Large, but the Clinical Questions Are Still Specific
Eleven trials, involving 1,614,689 patients, contributed to the meta-analysis. The size of that pooled sample suggests the field now has enough randomized data to begin asking comparative questions about effectiveness. Even so, the summary of the evidence in this excerpt stops short of providing the actual pooled effect estimates, the specific cardiovascular endpoints, or the direction of benefit across individual trial domains. Without those details, the most defensible conclusion is narrower: randomized evaluation of AI in cardiovascular care is now sizable, but the evidence base remains heterogeneous enough that interpretation depends heavily on how each algorithm was used.
In practice, that means a cardiology service considering AI adoption still needs more than a positive signal. It needs to know whether the tool improves diagnosis, speeds treatment, reduces errors, or changes hard outcomes—and whether it does so consistently across settings. A model that helps in one workflow may not translate to another if the implementation burden is too high or if the clinical decision it informs is too remote from patient benefit.
The review also makes clear that the field is moving faster than its long-term evidence. Most trials arriving after 2021 means the research base is still building around newer tools and newer deployment models. As a result, the current literature may be more informative about feasibility and near-term performance than about sustained cardiovascular benefit.
What This Evidence Base Can Support Right Now
This systematic review establishes that AI in cardiovascular care is no longer supported only by observational studies or single-center prototypes. Randomized trials now span multiple regions, multiple settings, and a very large patient base. The field has crossed an important threshold in quantity. What remains unsettled is whether those trials have produced a coherent, durable clinical advantage across the full spectrum of cardiovascular practice.
The strongest takeaway is methodological rather than celebratory: AI should be evaluated as a clinical intervention, not a software novelty. The next step is not more abstract enthusiasm, but more fully reported randomized evidence with longer follow-up, clearer implementation detail, and outcomes that matter to patients as much as they matter to algorithms. Until then, the gap between technical promise and clinical certainty remains the central limitation of the literature reviewed here.